Vance  Matthews

Dr. Vance Matthews

UWA School of Biomedical Sciences - Dobney Hypertension Centre Level 3, MRF Building, Rear 50 Murray Street, Perth WA 6000, Australia
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
RCRevathy Carnagarin
Revathy Carnagarin
KTKearney Tan
Kearney Tan
LALeon Adams
Leon Adams
VMVance Matthews
Vance Matthews
MKMarcio Kiuchi
Marcio Kiuchi
MSMarkus P SCHLAICH
Markus P SCHLAICH
Metabolic dysfunction-associated fatty liver disease (MAFLD) is the most common liver disease affecting a quarter of the global population and is often associated with adverse health outcomes. The increasing prevalence of MAFLD occurs in parallel to that of metabolic syndrome (MetS), which in fact plays a major role in driving the perturbations of cardiometabolic homeostasis. However, the mechanisms underpinning the pathogenesis of MAFLD are incompletely understood. Compelling evidence from animal and human studies suggest that heightened activation of the sympathetic nervous system is a key contributor to the development of MAFLD. Indeed, common treatment strategies for metabolic diseases such as diet and exercise to induce weight loss have been shown to exert their beneficial effects at least in part through the associated sympathetic inhibition. Furthermore, pharmacological and device-based approaches to reduce sympathetic activation have been demonstrated to improve the metabolic alterations frequently present in patients with obesity, MetSand diabetes. Currently available evidence, while still limited, suggests that sympathetic activation is of specific relevance in the pathogenesis of MAFLD and consequentially may offer an attractive therapeutic target to attenuate the adverse outcomes associated with MAFLD.

13 March 2019 in Biomedicines
Verified
Journal Article
Open access
PDF file
AMAaron L. Magno
Aaron L. Magno
LHLakshini Yasaswi Herat
Lakshini Yasaswi Herat
RCRevathy Carnagarin
Revathy Carnagarin
MSMarkus P SCHLAICH
Markus P SCHLAICH
VMVance Matthews
Vance Matthews
Healthy kidneys are important for the efficient regulation of metabolism. However, there is an ever increasing population of patients suffering from both acute and chronic kidney diseases that disrupt this homeostasis. This review will explore the emerging roles that interleukin 6 (IL-6) cytokine family members play in the pathogenesis of kidney disease. The IL-6 family of cytokines are involved in a diverse range of physiological functions. In relation to kidney disease, their involvement is no less diverse. Evidence from both preclinical and clinical sources show that IL-6 cytokine family members can play either a deleterious or protective role in response to kidney disease. This appears to be dependent on the type of kidney disease in question or the specific cytokine. Current attempts to use or target IL-6 cytokine family members as therapies of kidney diseases will be highlighted throughout this review. Finally, the involvement of IL-6 cytokine family members in kidney disease will be presented in the context of three regularly overlapping conditions: obesity, hypertension and diabetes.

2 March 2022 in Bioscience Reports
Verified
Journal Article
Open access
PDF file
JMJennifer Matthews
Jennifer Matthews
LHLakshini Herat
Lakshini Herat
JRJennifer Rooney
Jennifer Rooney
ERElizabeth Rakoczy
Elizabeth Rakoczy
MSMarkus Schlaich
Markus Schlaich
VMVance Matthews
Vance Matthews
Diabetes mellitus is a chronic metabolic disease that occurs when the pancreas is not producing enough insulin or when the insulin that it does produce is not able to be used effectively in the body. This results in hyperglycemia and if the blood sugars are not controlled, then it can lead to serious damage of various body systems, especially the nerves and the blood vessels. Uncontrolled diabetes is a major cause of kidney failure, heart attacks, stroke and amputation. One of the most devastating complications for patients is diabetic retinopathy (DR) which represents the leading cause of preventable vision loss in people between 20 and 65 years of age. Sodium glucose transporter 2 (SGLT2) inhibitors have been shown to reduce the risk for cardiovascular and renal events, however literature highlighting their potential role to prevent DR is limited. We therefore used a relevant mouse model (Akimba) to explore the effects of the SGLT2 inhibitor, Empagliflozin (EMPA), on the development of diabetic retinal changes. Here we show that when given in the early stages of type 1 diabetes (T1D), EMPA reduced the weight loss usually associated with T1D, decreased diabetes-associated polydipsia, lowered fasting blood glucose levels, decreased kidney-to-body weight ratios and, most importantly in the current context, substantially reduced retinal abnormalities associated with DR. We show that EMPA reduces vascular leakage indicated by lower albumin staining in the vitreous humor and diminishes expression of the pathogenic factor VEGF in the retina. Additionally, EMPA significantly alters the retinal genetic signature. Our findings suggest that SGLT2 inhibition may be a useful therapeutic approach to prevent the development of DR and its severity if given early in the disease process.

21 June 2020 in World Journal of Gastroenterology
Verified
Journal Article
Open access
LHLakshini Yasaswi Herat
Lakshini Yasaswi Herat
NWNatalie Ward
Natalie Ward
AMAaron L Magno
Aaron L Magno
ERElizabeth P Rakoczy
Elizabeth P Rakoczy
MKMarcio G Kiuchi
Marcio G Kiuchi
VMVance Matthews
Vance Matthews
Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice

5 July 2018 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
LHLakshini Yasaswi Herat
Lakshini Yasaswi Herat
VMVance Matthews
Vance Matthews
PRP. Elizabeth Rakoczy
P. Elizabeth Rakoczy
RCRevathy Carnagarin
Revathy Carnagarin
MSMarkus P SCHLAICH
Markus P SCHLAICH
The prevalence of diabetes is at pandemic levels in today’s society. Microvascular complications in organs including the eye are commonly observed in human diabetic subjects. Diabetic retinopathy (DR) is a prominent microvascular complication observed in many diabetics and is particularly debilitating as it may result in impaired or complete vision loss. In addition, DR is extremely costly for the patient and financially impacts the economy as a range of drug-related therapies and laser treatment may be essential. Prevention of microvascular complications is the major treatment goal of current therapeutic approaches; however, these therapies appear insufficient. Presently, sodium glucose cotransporter-2 (SGLT2) inhibitors may offer a novel therapy beyond simple glucose lowering. Excitingly, the EMPA-REG clinical trial, which focuses on the clinically used SGLT2 inhibitor empagliflozin, has been extremely fruitful and has highlighted beneficial cardiovascular and renal outcomes. The effects of SGLT2 inhibitors on DR are currently a topic of much research as outlined in the current review, but future studies are urgently needed to fully gain mechanistic insights. Here, we summarize current evidence and identify gaps that need to be addressed.

2 March 2022 in Current Hypertension Reports
Verified
Journal Article
Open access
PDF file
LHLakshini Yasaswi Herat
Lakshini Yasaswi Herat
JMJennifer Matthews
Jennifer Matthews
OAOmar Azzam
Omar Azzam
MSMarkus P. Schlaich
Markus P. Schlaich
VMVance Matthews
Vance Matthews
Purpose of Review: The moderate glucose-lowering effect of sodium glucose co-transporter 2 (SGLT2) inhibitors is unlikely to explain SGLT2 inhibitor-mediated beneficial outcomes, and unravelling the underlying mechanisms is a high priority in the research community. Given the dominant pathophysiologic role of the sympathetic nervous system activation in conditions such as hypertension and perturbed glucose homeostasis, it is pertinent to postulate that SGLT2 inhibitors may exert their beneficial effects at least in part via sympathetic inhibition.Recent Findings: SGLT2 inhibitors have shown enormous potential to improve cardiovascular outcomes in patients with type 2 diabetes, and their therapeutic potential is currently being investigated in a range of associated comorbidities such as heart failure and chronic kidney disease. Indeed, recent experimental data in relevant animal models highlight a bidirectional interaction between sympathetic nervous system activation and SGLT2 expression, and this facilitates several of the features associated with SGLT2 inhibition observed in clinical trials including improved glucose metabolism, weight loss, increased diuresis, and lowering of blood pressure.Summary: Currently available data highlight the various levels of interaction between the sympathetic nervous system and SGLT2 expression and explores the potential for SGLT2 inhibition as a therapeutic strategy in conditions commonly characterised by sympathetic activation.